Norstella
Citeline Podcasts
Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.
No dejes de visitar la web del podcast y apoyar a su creador: www.citeline.com
Autor
Norstella
Categoría
Web del podcast
Último episodio
19 de nov. de 2026
¿Dónde escuchar?
Podcasts en la app Replaio Radio Muy prontoLos podcasts llegarán muy pronto a la app. Instálala ahora y sé el primero en descubrir una forma totalmente nueva de vivir los podcasts
Episodios
Counting Self-Care’s Triple Win, With GSCF’s Greg Perry And Ben Carrick 05.10.2026 55:47
The Global Self-Care Federation has updated its analysis of the health, social and economic value of self-care, using data from 155 countries. Savings to health systems are up 21% to around $144bn a year, and for the first time the report looks in detail at self-care’s role in prevention. GSCF director general Greg Perry and Ben Carrick, co-chair of the federation’s policy committee, join HBW Insi...
Drug Fix: CMS Finalizes GLOBE Model And US FDA Adcomm, Personnel Changes 02.10.2026 31:03
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Senior Writer Cathy Kelly discuss the limited impact the US Centers for Medicare and Medicaid Services’ Global Benchmark for Efficient Drug Pricing (GLOBE) model after it was finalized with only a handful of participants (:58), as well as several other questions still being asked about it (10:24). They also consider the impa...
Proof of Concept - Can AI Outrun the Next Outbreak? 02.10.2026 39:40
What if you could design a diagnostic and a therapeutic directly from a pathogen's genetic code, faster than the disease can spread? Jared Bauer, co-founder and CEO of Seek Labs, joins Proof of Concept to explain how his company's AI engine maps conserved targets across 145+ pathogens to build programmable CRISPR therapeutics and rapid, lab-free diagnostics.
【3分で解説 #世界のファーマ】第31回 中国、バイオ医薬品の成長に本腰 初の5カ年計画 (Japanese-language podcast) Sept. 30, 2026 30.09.2026 3:16
世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。今回取り上げた記事はこちら Six Chinese Drugs On Course For Blockbuster Status As Five-Year Plan Sets The Bar https://insights.citeline.com/scrip/focus-on-asia/china/six-chinese-drugs-on-course-for-blockbuster-s...
Strategic Intent: Boehringer Ingelheim's Brian Hilberdink on Launching Into the GLP-1 Era 28.09.2026 30:04
Brian Hilberdink, President of US Human Pharma at Boehringer Ingelheim, joined Strategic Intent to talk about leading one of the company's most ambitious US launch periods in years, spanning a specialty drug in interstitial lung disease, an established franchise in cardiometabolic disease and a potential entry into the hyper-competitive obesity market. He discusses how private ownership shapes lon...
Drug Fix: Lessons From US FDA Commissioner Nominee Heidi Overton’s Confirmation Hearing 25.09.2026 29:37
Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs dissect US Food and Drug Administration commissioner nominee Heidi Overton’s answers during her Senate confirmation hearing and dominant themes (:58), rate the potential for her confirmation (13:14), as well as consider her responses to particular controversial iss...
Assessing the current dealmaking environment for psychedelic medicine. 24.09.2026 19:41
Joseph Haas and Emma Wille overview the dealmaking environment for psychedelic medicine given recent developments in the space: Eli Lilly's $2.8 billion acquisition of AtaiBeckley in July, the imminent FDA filing of Compass Pathways' COMP360 for treatment-resistant depression and a more relaxed regulatory environment for psychedelic therapies under the current administration.
Strategic Intent: Rubedo’s Seno-Adaptive Bet On Longevity Medicine 21.09.2026 40:09
In this episode of Strategic Intent, In Vivo senior reporter David Wild speaks with Frederick Beddingfield, CEO of Rubedo Life Sciences, about turning the biology of aging into real medicines. They discuss Rubedo’s lead topical GPX4 modulator RLS‑1496 in actinic keratosis, psoriasis, atopic dermatitis, and photo‑aged skin; a new push into androgenetic alopecia; and the company’s “seno-adaptive” ap...
Digital Health Roundup: Oura Plans IPO, FDA’s Home Health, Digital Tools For Alzheimer’s Detection 16.09.2026 21:02
In this month: Marion Webb highlights Oura’s IPO, new partnerships, and a class-action lawsuit. George Underwood discusses digital tools for early Alzheimer’s detection and Brian Bossetta FDA’s READI-Home Innovation Challenge. Shubham Singh interviews AI longevity firm BAiO.
Strategic Intent: Next‑Generation Cancer Vaccines And Nouscom’s Strategy For Interception And Personalization 15.09.2026 36:13
"Personalized and off‑the‑shelf cancer vaccines are moving from concept to clinic, raising new questions about differentiation, manufacturability, and commercial value. In this episode of Strategic Intent, In Vivo’s David Wild speaks with Marina Udier, CEO of Nouscom, about how the Basel‑based biotech is positioning its viral vector platform in this evolving landscape. They discuss NOUS‑209, an of...
Scaling Self-Care In Asia Pacific, With APSMI's Rachmadi Joesoef and Anama O'Reilly 15.09.2026 37:06
In this episode of Over the Counter, now also in video, HBW Insight talks to Rachmadi Joesoef, APSMI chair and CEO of Indonesian manufacturer PT Konimex, and Anama O'Reilly, who co-leads APSMI's public affairs and communications committee and heads public affairs for the ASEA zone at Opella, ahead of the association's joint congress with Self-CARER and GP Farmasi Indonesia in Bali. We cover why In...
Drug Fix: Increasing US FDA Leadership Stability And Where All The Adcomms Have Gone 11.09.2026 35:48
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter, Editor-in-Chief Nielsen Hobbs and Prevision Policy Founding Member Mike McCaughan consider the impact of Michael Davis and Karim Mikhail’s promotions to permanent directors of the US Food and Drug Administration’s Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, respectively (1:05), as w...
Strategic Intent: Evolving Requirements Of Life Sciences Leadership 08.09.2026 21:17
In this episode of Strategic Intent, Nick Stephens, chairman of the recruitment and executive placement company RSA group, looks at the state of executive leadership across the life sciences and biotech industries, reflecting on inflection points for hiring practices and emerging structural trends.
Drug Fix: US FDA Commissioner Nominee Heidi Overton’s Resume And COVID-19 Vaccine Trial Changes 04.09.2026 38:09
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter, Senior Reporter Maaisha Osman, and Editor-in-Chief Nielsen Hobbs discuss Heidi Overton’s financial and educational background as she begins navigating the path to US Food and Drug Administration commissioner confirmation (1:01), as well as an FDA incentive program that she would not be able to use to recruit additional staff sh...
Proof Of Concept: How A Charity Bridges Lab And Clinic 04.09.2026 21:27
Cancer Research UK is best known for funding science. But its commercial arm, Cancer Research Horizons, does something less obvious: it builds companies. This episode features Phil Masterson and Neil Jones, who run its ventures and drug discovery arms, unpacking why charities are increasingly bridging the gap between a promising result in the lab and a medicine in the clinic. Drug discovery, oncol...
Off-Patent, On Record: A Story Of Patients Fighting For Accessible Cystic Fibrosis Treatment 02.09.2026 22:34
In the second episode of Off-Patent, On Record, Generics Bulletin’s senior reporter Urtė Fultinavičiūtė hears how patients with cystic fibrosis travelled to Bangladesh to collect generic version of Vertex’s highly inaccessible Trikafta. Urtė is joined by Wilna Lottering and her son Josh from South Africa, as well as Gayle Pledger, a cystic fibrosis campaigner.
Strategic Intent: Beyond The Breakthrough - From Approval To Adoption 01.09.2026 40:23
A medical device can work beautifully and still go nowhere. In this episode of Strategic Intent, Krishna Eluri sits down with Mark Saxton, U.S. CEO of Baird Medical, who has spent more than 25 years bringing first-of-their-kind procedural technologies to market. Their conversation digs into medtech's hardest problem — not inventing a technology, but getting physicians to switch and payers to cover...
Making The Case For Switch, With AESGP’s Christelle Anquez-Traxler 01.09.2026 28:26
Products like ibuprofen and loratadine are now grabbed off a pharmacy shelf without a second thought, but both started out as prescription-only medicines. The process that moves a drug from one to the other, known as Rx-to-OTC switch, is one of the most reliable forms of innovation in self-care, and yet it happens less often than the industry would like. In this episode of Over the Counter, now al...
ZS On How AI is Reshaping The Patient's Approach to Care Delivery - a View From the US, China and Germany 31.08.2026 35:30
A landmark three-country survey by the ZS consulting and technology firm , which shows the rapid trend towards patients' uptake of AI tools that empower them on their healthcare journeys. ZS’ Jon Roffman and Bhargav Mantha set the scene.
Drug Fix: MFN Finds Mid-Size Companies And More Vaccine Policy Moves 28.08.2026 29:33
Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the potential differences between Most Favored Nation drug pricing agreements for small and mid-size companies and the largest pharmas (1:03), as well as the impact of potential vaccine policy changes on the US public health apparatus (15:10). More O...
【3分で解説 #世界のファーマ】第30回 米国、ジェネリック関税に国内外から懸念/BMSとAZ合併の噂 (Japanese-language podcast) Aug. 28, 2026 28.08.2026 3:52
世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。今回取り上げた記事はこちら. As US Threatens A Tariff Bomb On Generic Drugs, Will Exemptions Be Negotiated? https://insights.citeline.com/pink-sheet/policy-regulation/as-us-threatens-a-tariff-bomb-on-generic-dru...
Videocast: Goodwin’s Sophie McGrath – A Legal View Of Healthtech And Biopharma Trends 25.08.2026 40:30
A videocast for the In Vivo podcast section, with Goodwin's Sophie McGrath - talking about healthtech and pharma trends. Innovation, investment, legal, Goodwin, Sophie McGrath, EU, Europe
Drug Fix: What FDA Commissioner Nominee Heidi Overton Will Mean For The Agency 22.08.2026 30:10
Pink Sheet Editor-in-Chief Nielsen Hobbs, executive editor Derrick Gingery, and senior reporter Maaisha Osman discuss new FDA commissioner nominee Heidi Overton, her prospects for confirmation, and what her pick means for the agency. More On The Topic From The Pink Sheet FDA Commissioner Nominee Has The White House’s Trust. Winning Over Career Staff Is Another Matter: https://insights.citeline.com...
Bonus Episode: Inside Endocyclic’s Precision Peptide Strategy For Endometriosis Diagnosis And Treatment 21.08.2026 32:49
One in ten women has endometriosis, yet treatment options remain largely unchanged for decades. Tanya Petrossian, CEO of EndoCyclic Therapeutics, explains how her company's non-hormonal peptide platform - now FDA-cleared for human trials - could finally change that.
Podcasts similares
Replaio no es editor de podcasts; los nombres de los programas, las portadas y el audio pertenecen a sus autores y se distribuyen a través de canales RSS públicos